期刊
JOURNAL OF INFECTIOUS DISEASES
卷 210, 期 12, 页码 1972-1980出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiu351
关键词
ivermectin; malaria; mass drug administration; mass screen and treat
资金
- Bill and Melinda Gates Foundation
- Medical Research Council (MRC)
- Bill and Melinda Gates Foundation [OPP1034789]
- MRC [G1002387, MR/K010174/1] Funding Source: UKRI
- Medical Research Council [MR/K010174/1, G1002387, MR/K010174/1B] Funding Source: researchfish
- Bill and Melinda Gates Foundation [OPP1034789] Funding Source: Bill and Melinda Gates Foundation
Ivermectin (IVM), used alongside mass treatment strategies with an artemisinin combination therapy, has been suggested as a possible tool for reducing malaria transmission. Mosquitoes ingesting a bloodmeal containing IVM have increased mortality, reducing the probability that the parasite completes sporogony. Human pharmacokinetic data and mortality data for mosquitoes taking bloodmeals containing IVM are used to quantify the mosquitocidal effect of IVM. These are incorporated into a transmission model to estimate the impact of IVM in combination with mass treatment strategies with artemether-lumefantrine on transmission metrics. Adding IVM increases the reductions in parasite prevalence achieved and delays the reemergence of parasites compared to mass treatment alone. This transmission effect is obtained through its effect on vector mortality. IVM effectiveness depends on coverage with the highest impact achieved if given to the whole population rather than only those with existing detectable parasites. Our results suggest that including IVM in a mass treatment strategy can reduce the time taken to interrupt transmission as well as help to achieve transmission interruption in transmission settings in which mass treatment strategies alone would be insufficient. Including IVM in mass treatment strategies could be a useful adjunct to reduce and interrupt malaria transmission.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据